Immix Approved to Begin Phase 1/2a Study of Flagship Candidate

LOS ANGELES, Jan. 5, 2018 /PRNewswire/ -- Immix Biopharma, Inc., is proud to announce it has received Human Research Ethics Committee (IRB) approval to begin a Phase 1/2a Open-Label, Dose-Escalation/Dose-Expansion Safety, Tolerability and Pharmacokinetic Study of IMX-110 in Participants with Advanced Solid Tumors ( https://clinicaltrials.gov/ct2/show/NCT03382340 ).

In preclinical studies, Immix flagship platform candidate Imx-110 demonstrated efficacy against pancreatic, gliobastoma, triple negative breast, colorectal, multiple myeloma and ovarian cancer models. Preclinical data from a syngeneic KPC pancreatic cancer model demonstrated not only a marked reduction in tumor size, but also a wholesale rearrangement of the immune system and tumor microenvironment with near complete disappearance of regulatory T and endothelial cells from tumor foci with simultaneous tumor infiltration by CD8 lymphocytes post-treatment.

This cross-tumor efficacy in diverse models is a testament to the far-reaching potential of the approach employed by Immix. "By creating a combination therapy which attacks the root drivers of cancer's evolutionary adaptability and resistance to any therapy, we have the chance to really change the paradigm of chasing tumor adaptations and provide meaningful benefit to cancer patients," shares CEO and co-founder Ilya Rachman, MD, PhD, MBA.

Imx-110 is a first-in-class combination therapy designed to inhibit cancer resistance and evolvability, while inducing apoptosis. Imx-110 contains NF-kB/Stat3/pan-tyrosine kinase inhibitor curcumin combined with a small amount of doxorubicin, encased in a nano-sized delivery system for optimal tumor penetration. The nanoparticle is tunable in that it can be bound to various targeting moieties – delivering even more payload to tumors or other cell populations of interest, if needed.

The study's Principal Investigator Professor de Souza shared, "We are excited to be able to partner with Immix in conducting this first-in-human study with a promising novel nanoparticle. I look forward to seeing what it can do in cancers that are traditionally difficult to treat." To stay updated on the latest clinical results or for queries, please contact:

Ryan Witt
Vice President
Immix Biopharma, Inc.
E: [email protected]

About the Company
Immix Biopharma, Inc. is a privately held, biopharmaceutical firm focused on developing safe and effective therapies for cancer patients. The team was founded by Vladimir Torchilin, PhD, D.Sc. Director of the Center for Pharmaceutical Biotechnology and Nanomedicine at Northeastern University; Ilya Rachman, an MD, PhD, MBA, physician scientist and clinical researcher; and Sean D. Senn, JD, MSc., MBA, a senior biotechnology patent attorney and fund manager. The company's goal is to harness scientific advances in order to engineer transformative, effective cancer treatments.

About Professor Paul de Souza:

Professor de Souza is Foundation Chair of Medical Oncology at Western Sydney University and is a practicing medical oncologist at Liverpool Hospital, St George Private Hospital, South West Private Hospital, and Southside Cancer Care Centre. He runs a research laboratory at the Ingham Institute in Sydney, and is dedicated to developing new drugs for cancer patients and innovative methodologies for monitoring of cancers, and running many clinical trials.

After completion of his medical oncology training in Sydney, Paul was appointed as a Research Associate and later an Assistant Professor of Medicine at the University of Virginia where he developed his clinical and research interests in cancer drug development.

Professor de Souza's Qualifications:

BScMed MB BS MPH Syd, PhD, FRACP
Professor de Souza's Society Memberships & Professional Activities:
ASCO, AACR, SNO, MOG, COSA

SOURCE Immix Biopharma, Inc.